Principal Financial Group Inc. Sells 8,670 Shares of SciClone Pharmaceuticals, Inc. (SCLN)

Principal Financial Group Inc. decreased its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 2.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 395,044 shares of the specialty pharmaceutical company’s stock after selling 8,670 shares during the quarter. Principal Financial Group Inc. owned 0.76% of SciClone Pharmaceuticals worth $4,424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. GLG Partners LP lifted its position in SciClone Pharmaceuticals by 337.5% in the second quarter. GLG Partners LP now owns 1,588,897 shares of the specialty pharmaceutical company’s stock valued at $17,478,000 after purchasing an additional 1,225,709 shares during the last quarter. Renaissance Technologies LLC lifted its position in SciClone Pharmaceuticals by 21.9% in the second quarter. Renaissance Technologies LLC now owns 2,540,200 shares of the specialty pharmaceutical company’s stock valued at $27,942,000 after purchasing an additional 456,100 shares during the last quarter. GAM Holding AG bought a new stake in SciClone Pharmaceuticals in the second quarter valued at approximately $4,261,000. Vanguard Group Inc. lifted its position in SciClone Pharmaceuticals by 9.2% in the first quarter. Vanguard Group Inc. now owns 2,948,846 shares of the specialty pharmaceutical company’s stock valued at $28,899,000 after purchasing an additional 248,785 shares during the last quarter. Finally, Marshall Wace North America L.P. lifted its position in SciClone Pharmaceuticals by 1,142.0% in the second quarter. Marshall Wace North America L.P. now owns 242,684 shares of the specialty pharmaceutical company’s stock valued at $2,670,000 after purchasing an additional 223,144 shares during the last quarter. Institutional investors own 72.80% of the company’s stock.

Shares of SciClone Pharmaceuticals, Inc. (SCLN) opened at $11.15 on Monday. SciClone Pharmaceuticals, Inc. has a 12-month low of $8.55 and a 12-month high of $11.43.

ILLEGAL ACTIVITY NOTICE: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/12/11/principal-financial-group-inc-sells-8670-shares-of-sciclone-pharmaceuticals-inc-scln.html.

SciClone Pharmaceuticals Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply